Get started with Synapticure
Your CMS GUIDE Partner for Specialized Dementia Support
Cutting-Edge Treatment
Welcome to the Synapticure community and thank you for taking the first steps to getting expert care for Dementia. We're truly honored to have you with us.
By registering, you’re not only exploring potential care options for yourself or a loved one — including access to cutting-edge treatments like Amyloid Therapies— you’re also contributing to research that could make a real difference for others facing similar challenges. We’re deeply grateful for your willingness to be part of this important work.
The Synapticure Way
When you begin your journey with us, you can expect to:
Schedule Intake
Book a no-cost virtual intake with us. We’ll answer questions, offer guidance and help with care navigation.
Meet Your Dedicated Care Team
You’ll meet our dedicated team of professionals, here to support you every step of the way. Our team are experts in amyloid therapies, and Alzheimer’s clinical trials.
Get a Care Plan
A personalized care plan is built around your daily needs at home.
Receive 24/7 Support
Receive day and night access to care coordination services.*If you opt-in
Our Experts
Oleg Yerstein
Director of Cognitive Care Service Line, Neurologist
Former Director of the Center for Memory and Cognitive Disorders at Beth Israel Lahey Health, Dr. Yerstein brings extensive expertise in dementia biomarkers, anti-amyloid therapies, and Alzheimer’s clinical trials.
Noreen Flanagan
Director of Behavioral Health, Psychiatrist
Dr. Flanagan has dedicated over 20 years to neurodegenerative care, pioneering interdisciplinary programs in Memory Clinic and tele-psychiatry to ensure comprehensive care for all, now continuing her passion at Synapticure.
Jeremy Pruzin
Cognitive Neurologist
Dr. Jeremy Pruzin is a behavioral neurologist researching and treating Alzheimer’s and related dementias, with a focus on prevention through lifestyle and risk factor management.
In-network coverage for all 50 states
Please note that we may be considered out-of-network with your insurance provider. Coverage and reimbursement may vary depending on your specific plan. We recommend contacting your insurance company directly to confirm your out-of-network benefits before your visit. If you have any questions or need assistance with this process, our team is happy to help.
Hear why Patients and Caregivers love Synapticure
Dedicated Support at Every Step
Frequently Asked Questions
Visit our full FAQ page for more commonly asked questions.
What are Amyloid Therapies?
Amyloid therapies, which currently include lecanemab and donanemab, are a new class of medications that work by clearing amyloid from the brain. Amyloid is a key protein that accumulates into abnormal plaques involved in Alzheimer’s disease.
How do I know if Amyloid Therapy is safe and right for me?
We’ll need the following records to help you make a decision on treatment:
Step 1: Confirm the Diagnosis. These therapies are only for people in the early stages of Alzheimer’s disease (mild cognitive impairment or mild dementia). They are not a cure, they slow the progression of symptoms by about 30-40%.
Your care team, led by a memory specialist, will review your history, any prior testing completed elsewhere, and current symptoms, perform cognitive testing, and may recommend blood work, a brain MRI or additional testing to make a diagnosis.
Step 2: Confirm pathologic accumulation of Amyloid in the Brain. Proof of amyloid buildup is required before treatment. This can be shown through:
- An amyloid PET scan, or
- A blood test (in some cases, to help guide next steps, though expect to need a spinal fluid or PET test in most cases to confirm eligibility). or
- For patients who have had it done already, spinal fluid (lumbar puncture) test results may be sufficient to determine if there are amyloid plaques in the brain.
Step 3: Complete a Safety Screen. We’ll need:
- MRI: A brain MRI to understand eligibility for treatment and if eligible, to make sure the risk of amyloid-related imaging abnormalities (ARIA), a potential side effect of small bleeds or temporary swelling, is known and acceptable to you and your care team. We can help you get this test done, or use an existing recent MRI if you have one.
- Genetic testing: A genetic test for the APOE gene – different APOE genes affect risk for ARIA. We can do this from your home or in a local lab.
Your medical history, medications (especially blood thinners), and blood pressure will also be reviewed, some medications cannot be taken with these treatments. We’ll work with your current medical team to collect this on your behalf.
What should I know about the side effects of ARIA?
- Risk for ARIA largely depends on a person's APOE genes and findings on the brain MRI prior to starting treatment - it can range from less than 5% to about a 30% chance of occurring.
- ARIA generally does not cause symptoms, if it does occur, it is usually found on MRIs done to monitor treatment, symptomatic ARIA generally occurs in less than 2% of persons treated.
- The most common symptom of ARIA is headache, other symptoms include balance problems, dizziness, visual changes, and temporary worsening of confusion.
- Swelling related to ARIA resolves on its own with time.
- ARIA, especially the small bleeds, also occur in the absence of treatment, but are more common with treatment.
- If swelling related to ARIA occurs, treatment can usually be resumed after the swelling has resolved on its own. There are however some instances when treatment must be discontinued.
How do I begin Amyloid Therapy?
Once your care team has confirmed the diagnosis, the presence of abnormal amyloid levels, and finished the safety screens including a discussion of risks and benefits of treatment, your case may then need to be presented to our panel of clinical and patient safety experts to approve treatment. Our care team will then work with you and your insurance company to find and book you into an infusion center to support ongoing care.
How often are treatments given?
These medications are currently given by IV infusion, either every 2 or every 4 weeks, in an infusion center or clinic.
Follow-up MRIs are required during the first year to monitor the brain for potential side effects of swelling or small bleeds, which are the two forms of ARIA.
Your care team will also monitor your memory, daily function, and any new symptoms.
Initial treatment continues until amyloid plaque is cleared from the brain, which usually takes 6-18 months.
How long will I need treatments for?
Treatment decisions are individualized — your neurologist and care team will discuss the potential benefits, risks, and what to expect over time.
Even while on therapy, it’s important to continue healthy lifestyle habits, control other medical conditions like high blood pressure, and attend regular follow-up visits.
Options for ongoing treatment after the initial 6–18-month period during which amyloid plaque is cleared should be discussed with your doctor.